Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis.
Identifieur interne : 000396 ( Main/Corpus ); précédent : 000395; suivant : 000397Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis.
Auteurs : J. Castilla ; J. Moran ; V. Martinez-Artola ; G. Reina ; I. Martinez-Baz ; M. Garcia Cenoz ; N. Alvarez ; F. Irisarri ; M. Arriazu ; F. Elia ; E. SalcedoSource :
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [ 1560-7917 ] ; 2011.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Child (MeSH), Child, Preschool (MeSH), Chronic Disease (MeSH), Confidence Intervals (MeSH), Disease Outbreaks (prevention & control), Female (MeSH), Humans (MeSH), Incidence (MeSH), Infant (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (immunology), Influenza Vaccines (therapeutic use), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Male (MeSH), Middle Aged (MeSH), Population Surveillance (MeSH), Primary Health Care (MeSH), Prospective Studies (MeSH), Seasons (MeSH), Spain (epidemiology), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , immunology : Influenza Vaccines.
- geographic , epidemiology : Spain.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza, Human.
- prevention & control : Disease Outbreaks, Influenza, Human.
- chemical , therapeutic use : Influenza Vaccines.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Chronic Disease, Confidence Intervals, Female, Humans, Incidence, Infant, Male, Middle Aged, Population Surveillance, Primary Health Care, Prospective Studies, Seasons, Treatment Outcome, Young Adult.
Abstract
We defined a cohort of people with major chronic conditions (152,585 subjects) in Navarre, Spain, using electronic records from physicians, to obtain 2010/11 mid-season estimates of influenza vaccine effectiveness. The adjusted estimates of the effectiveness of the 2010/11 trivalent influenza vaccine were 31% (95% confidence interval (CI): 20–40%) in preventing medically attended influenza-like illness, and 58% (95% CI: 11–80%) in preventing laboratory-confirmed influenza. Having received the monovalent influenza A(H1N1)2009 vaccine in the 2009/10 season had an independent preventive effect against medically attended influenza-like illness (17%, 95% CI: 1–30%), and having received both vaccines had 68% (95% CI: 23–87%) effectiveness in preventing laboratory-confirmed influenza.
PubMed: 21345321
Links to Exploration step
pubmed:21345321Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis.</title>
<author><name sortKey="Castilla, J" sort="Castilla, J" uniqKey="Castilla J" first="J" last="Castilla">J. Castilla</name>
<affiliation><nlm:affiliation>Public Health Institute of Navarre, Pamplona, Spain. jcastilc@navarra.es</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moran, J" sort="Moran, J" uniqKey="Moran J" first="J" last="Moran">J. Moran</name>
</author>
<author><name sortKey="Martinez Artola, V" sort="Martinez Artola, V" uniqKey="Martinez Artola V" first="V" last="Martinez-Artola">V. Martinez-Artola</name>
</author>
<author><name sortKey="Reina, G" sort="Reina, G" uniqKey="Reina G" first="G" last="Reina">G. Reina</name>
</author>
<author><name sortKey="Martinez Baz, I" sort="Martinez Baz, I" uniqKey="Martinez Baz I" first="I" last="Martinez-Baz">I. Martinez-Baz</name>
</author>
<author><name sortKey="Garcia Cenoz, M" sort="Garcia Cenoz, M" uniqKey="Garcia Cenoz M" first="M" last="Garcia Cenoz">M. Garcia Cenoz</name>
</author>
<author><name sortKey="Alvarez, N" sort="Alvarez, N" uniqKey="Alvarez N" first="N" last="Alvarez">N. Alvarez</name>
</author>
<author><name sortKey="Irisarri, F" sort="Irisarri, F" uniqKey="Irisarri F" first="F" last="Irisarri">F. Irisarri</name>
</author>
<author><name sortKey="Arriazu, M" sort="Arriazu, M" uniqKey="Arriazu M" first="M" last="Arriazu">M. Arriazu</name>
</author>
<author><name sortKey="Elia, F" sort="Elia, F" uniqKey="Elia F" first="F" last="Elia">F. Elia</name>
</author>
<author><name sortKey="Salcedo, E" sort="Salcedo, E" uniqKey="Salcedo E" first="E" last="Salcedo">E. Salcedo</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21345321</idno>
<idno type="pmid">21345321</idno>
<idno type="wicri:Area/Main/Corpus">00396</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00396</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis.</title>
<author><name sortKey="Castilla, J" sort="Castilla, J" uniqKey="Castilla J" first="J" last="Castilla">J. Castilla</name>
<affiliation><nlm:affiliation>Public Health Institute of Navarre, Pamplona, Spain. jcastilc@navarra.es</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Moran, J" sort="Moran, J" uniqKey="Moran J" first="J" last="Moran">J. Moran</name>
</author>
<author><name sortKey="Martinez Artola, V" sort="Martinez Artola, V" uniqKey="Martinez Artola V" first="V" last="Martinez-Artola">V. Martinez-Artola</name>
</author>
<author><name sortKey="Reina, G" sort="Reina, G" uniqKey="Reina G" first="G" last="Reina">G. Reina</name>
</author>
<author><name sortKey="Martinez Baz, I" sort="Martinez Baz, I" uniqKey="Martinez Baz I" first="I" last="Martinez-Baz">I. Martinez-Baz</name>
</author>
<author><name sortKey="Garcia Cenoz, M" sort="Garcia Cenoz, M" uniqKey="Garcia Cenoz M" first="M" last="Garcia Cenoz">M. Garcia Cenoz</name>
</author>
<author><name sortKey="Alvarez, N" sort="Alvarez, N" uniqKey="Alvarez N" first="N" last="Alvarez">N. Alvarez</name>
</author>
<author><name sortKey="Irisarri, F" sort="Irisarri, F" uniqKey="Irisarri F" first="F" last="Irisarri">F. Irisarri</name>
</author>
<author><name sortKey="Arriazu, M" sort="Arriazu, M" uniqKey="Arriazu M" first="M" last="Arriazu">M. Arriazu</name>
</author>
<author><name sortKey="Elia, F" sort="Elia, F" uniqKey="Elia F" first="F" last="Elia">F. Elia</name>
</author>
<author><name sortKey="Salcedo, E" sort="Salcedo, E" uniqKey="Salcedo E" first="E" last="Salcedo">E. Salcedo</name>
</author>
</analytic>
<series><title level="j">Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</title>
<idno type="eISSN">1560-7917</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Chronic Disease (MeSH)</term>
<term>Confidence Intervals (MeSH)</term>
<term>Disease Outbreaks (prevention & control)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Incidence (MeSH)</term>
<term>Infant (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Influenza, Human (virology)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Population Surveillance (MeSH)</term>
<term>Primary Health Care (MeSH)</term>
<term>Prospective Studies (MeSH)</term>
<term>Seasons (MeSH)</term>
<term>Spain (epidemiology)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Chronic Disease</term>
<term>Confidence Intervals</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Infant</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Population Surveillance</term>
<term>Primary Health Care</term>
<term>Prospective Studies</term>
<term>Seasons</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We defined a cohort of people with major chronic conditions (152,585 subjects) in Navarre, Spain, using electronic records from physicians, to obtain 2010/11 mid-season estimates of influenza vaccine effectiveness. The adjusted estimates of the effectiveness of the 2010/11 trivalent influenza vaccine were 31% (95% confidence interval (CI): 20–40%) in preventing medically attended influenza-like illness, and 58% (95% CI: 11–80%) in preventing laboratory-confirmed influenza. Having received the monovalent influenza A(H1N1)2009 vaccine in the 2009/10 season had an independent preventive effect against medically attended influenza-like illness (17%, 95% CI: 1–30%), and having received both vaccines had 68% (95% CI: 23–87%) effectiveness in preventing laboratory-confirmed influenza.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21345321</PMID>
<DateCompleted><Year>2011</Year>
<Month>04</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>05</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1560-7917</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>16</Volume>
<Issue>7</Issue>
<PubDate><Year>2011</Year>
<Month>Feb</Month>
<Day>17</Day>
</PubDate>
</JournalIssue>
<Title>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</Title>
<ISOAbbreviation>Euro Surveill.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">19799</ELocationID>
<Abstract><AbstractText>We defined a cohort of people with major chronic conditions (152,585 subjects) in Navarre, Spain, using electronic records from physicians, to obtain 2010/11 mid-season estimates of influenza vaccine effectiveness. The adjusted estimates of the effectiveness of the 2010/11 trivalent influenza vaccine were 31% (95% confidence interval (CI): 20–40%) in preventing medically attended influenza-like illness, and 58% (95% CI: 11–80%) in preventing laboratory-confirmed influenza. Having received the monovalent influenza A(H1N1)2009 vaccine in the 2009/10 season had an independent preventive effect against medically attended influenza-like illness (17%, 95% CI: 1–30%), and having received both vaccines had 68% (95% CI: 23–87%) effectiveness in preventing laboratory-confirmed influenza.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castilla</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Public Health Institute of Navarre, Pamplona, Spain. jcastilc@navarra.es</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Moran</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Martinez-Artola</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y"><LastName>Reina</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Martinez-Baz</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Garcia Cenoz</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Alvarez</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Irisarri</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Arriazu</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Elia</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Salcedo</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>02</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Sweden</Country>
<MedlineTA>Euro Surveill</MedlineTA>
<NlmUniqueID>100887452</NlmUniqueID>
<ISSNLinking>1025-496X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Euro Surveill. 2011;16(11). pii: 19821</RefSource>
<PMID Version="1">21435331</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002908" MajorTopicYN="Y">Chronic Disease</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>2</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>2</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21345321</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000396 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000396 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= GrippeEspagneV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:21345321 |texte= Effectiveness of trivalent seasonal and monovalent influenza A(H1N1)2009 vaccines in population with major chronic conditions of Navarre, Spain: 2010/11 mid-season analysis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:21345321" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a GrippeEspagneV1
This area was generated with Dilib version V0.6.37. |